Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Xcyte Digital Corp. Signs Agreement to Purchase Assets of Webinar.net (click to learn more) Viva Gold Reports Multiple High-Grade Gold Hits at the Tonopah Gold Project (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Spero Therapeutics Inc SPRO

Healthcare Biotechnology
Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections with unmet need. Its lead product candidate, SPR720, is an oral antimicrobial agent in development for the treatment of nontuberculous mycobacterial (NTM) pulmonary disease... see more

Recent & Breaking News (NDAQ:SPRO)

Spero Therapeutics Announces Closing of Exclusive License Agreement with GSK for Tebipenem HBr

GlobeNewswire November 8, 2022

Spero Therapeutics to Provide Business Update and Report Third Quarter 2022 Financial Results on Monday, November 14, 2022

GlobeNewswire November 7, 2022

Spero Therapeutics to Present Data at IDWeek 2022

GlobeNewswire October 19, 2022

Spero Therapeutics to Host Virtual R&D Event on Non-Tuberculous Mycobacterial Pulmonary Disease and the SPR720 Program

GlobeNewswire October 3, 2022

GSK and Spero Therapeutics Announce Exclusive License Agreement for Late-Stage Antibiotic Asset, Tebipenem HBr

GlobeNewswire September 22, 2022

Spero Therapeutics Announces Appointment of Kamal Hamed, MD, MPH, MBA, as Chief Medical Officer

GlobeNewswire September 15, 2022

Spero Therapeutics to Present at Upcoming Investor Conference

GlobeNewswire September 7, 2022

Spero Therapeutics Provides Tebipenem HBr Program Update Following Type A Meeting with the U.S. Food and Drug Administration

GlobeNewswire September 6, 2022

Spero Therapeutics Announces Second Quarter 2022 Operating Results and Provides Business Update

GlobeNewswire August 10, 2022

Spero Therapeutics to Provide Business Update and Report Second Quarter 2022 Financial Results on Wednesday, August 10, 2022

GlobeNewswire August 9, 2022

DEADLINE ALERT: Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of July 25, 2022 in Spero Lawsuit - SPRO

Newsfile July 25, 2022

SHAREHOLDER ALERT FILING DEADLINE TODAY: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Spero Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - SPRO

PR Newswire July 25, 2022

SPRO FINAL DEADLINE TODAY: ROSEN, A GLOBALLY RECOGNIZED FIRM, Encourages Spero Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important July 25 Deadline in Securities Class Action - SPRO

Newsfile July 25, 2022

Bronstein, Gewirtz & Grossman, LLC Reminds Spero Therapeutics, Inc. (SPRO) Shareholders of Class Action Deadline and Last Few Hours to Actively Participate

Business Wire July 25, 2022

FINAL DEADLINE ALERT: The Schall Law Firm Encourages Investors in Spero Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

PR Newswire July 25, 2022

DEADLINE TODAY: The Schall Law Firm Encourages Investors in Spero Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

Newsfile July 25, 2022

CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Spero Investors of a Lead Plaintiff Deadline of July 25, 2022

PR Newswire July 25, 2022

Spero Class Action: Levi & Korsinsky Reminds Spero Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 25, 2022 - SPRO

Newsfile July 22, 2022

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Spero Therapeutics, Inc. (SPRO)

Business Wire July 22, 2022

SPRO FINAL DEADLINE ALERT: TOP RANKED ROSEN LAW FIRM Encourages Spero Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important July 25 Deadline in Securities Class Action - SPRO

Newsfile July 22, 2022